7 Biotechnology Stocks to Buy Now

The grades of 7 Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This is a strong week for CoLucid Pharmaceuticals, Inc. (CLCD). The company’s rating climbs to A from the previous week’s B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CLCD stock.

Aimmune Therapeutics Inc (AIMT) improves from a C to a B rating this week. For more information, get Portfolio Grader’s complete analysis of AIMT stock.

Vanda Pharmaceuticals Inc. (VNDA) is seeing ratings go up from a B last week to a A this week. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of VNDA stock.

ARIAD Pharmaceuticals, Inc. (ARIA) gets a higher grade this week, advancing from a B last week to a A. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARIA stock.

Chemocentryx, Inc. (CCXI) shows solid improvement this week. The company’s rating rises from a C to a B. Chemocentryx, Inc. a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of CCXI stock.

Array BioPharma Inc. (ARRY) earns a B this week, jumping up from last week’s grade of C. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. The company also gets A’s in sales growth. For more information, get Portfolio Grader’s complete analysis of ARRY stock.

The rating of Macrocure Ltd. (MCUR) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of MCUR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/7-biotechnology-stocks-to-buy-now-5/.

©2020 InvestorPlace Media, LLC